MannKind (MNKD) Competitors $3.80 +0.05 (+1.20%) As of 10:01 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNKD vs. ALKS, LGND, FOLD, BCRX, CLDX, DVAX, NVAX, INVA, OPK, and GERNShould you be buying MannKind stock or one of its competitors? The main competitors of MannKind include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Novavax (NVAX), Innoviva (INVA), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry. MannKind vs. Its Competitors Alkermes Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals Celldex Therapeutics Dynavax Technologies Novavax Innoviva OPKO Health Geron MannKind (NASDAQ:MNKD) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership. Which has more risk & volatility, MNKD or ALKS? MannKind has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Which has better valuation & earnings, MNKD or ALKS? Alkermes has higher revenue and earnings than MannKind. Alkermes is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMannKind$285.50M4.04$27.59M$0.1037.95Alkermes$1.56B2.78$367.07M$2.0812.60 Do insiders and institutionals have more ownership in MNKD or ALKS? 49.6% of MannKind shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 3.0% of MannKind shares are held by company insiders. Comparatively, 4.4% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is MNKD or ALKS more profitable? Alkermes has a net margin of 23.15% compared to MannKind's net margin of 10.12%. Alkermes' return on equity of 24.86% beat MannKind's return on equity.Company Net Margins Return on Equity Return on Assets MannKind10.12% -32.41% 10.85% Alkermes 23.15%24.86%17.14% Does the media prefer MNKD or ALKS? In the previous week, Alkermes had 23 more articles in the media than MannKind. MarketBeat recorded 31 mentions for Alkermes and 8 mentions for MannKind. Alkermes' average media sentiment score of 0.95 beat MannKind's score of 0.57 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 12 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend MNKD or ALKS? MannKind currently has a consensus target price of $9.86, indicating a potential upside of 159.74%. Alkermes has a consensus target price of $41.08, indicating a potential upside of 56.78%. Given MannKind's stronger consensus rating and higher possible upside, equities analysts clearly believe MannKind is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MannKind 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83 SummaryAlkermes beats MannKind on 11 of the 17 factors compared between the two stocks. Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNKD vs. The Competition Export to ExcelMetricMannKindMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.15B$3.02B$5.54B$9.48BDividend YieldN/A2.45%4.74%4.13%P/E Ratio37.9517.7728.9423.96Price / Sales4.04282.76412.94176.66Price / Cash27.0240.5624.4827.20Price / Book-13.098.478.475.70Net Income$27.59M-$54.98M$3.25B$265.26M7 Day Performance-4.17%-3.41%-1.22%-2.41%1 Month Performance5.27%15.62%7.82%6.73%1 Year Performance-28.93%6.45%27.10%20.03% MannKind Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNKDMannKind3.4092 of 5 stars$3.80+1.2%$9.86+159.7%-29.8%$1.15B$285.50M37.95400Upcoming EarningsAnalyst DowngradeALKSAlkermes4.7517 of 5 stars$26.15+0.1%$40.92+56.5%-4.2%$4.31B$1.56B12.511,800Earnings ReportAnalyst RevisionLGNDLigand Pharmaceuticals4.1832 of 5 stars$134.92-0.7%$147.17+9.1%+32.5%$2.60B$167.13M-18.9580Positive NewsUpcoming EarningsFOLDAmicus Therapeutics4.001 of 5 stars$6.12+1.0%$16.22+165.1%-37.3%$1.88B$528.29M-67.99480News CoverageAnalyst UpgradeBCRXBioCryst Pharmaceuticals4.2373 of 5 stars$8.26-3.4%$16.70+102.2%+13.2%$1.73B$503.49M-31.77530News CoverageEarnings ReportCLDXCelldex Therapeutics1.2642 of 5 stars$22.01-5.7%$50.11+127.7%-36.2%$1.46B$7.02M-8.15150News CoverageEarnings ReportDVAXDynavax Technologies4.1965 of 5 stars$11.29-0.6%$24.00+112.6%+3.1%$1.36B$277.25M-21.71350Upcoming EarningsNVAXNovavax4.5823 of 5 stars$7.28-2.5%$15.86+117.8%-44.3%$1.18B$682.16M2.751,990Upcoming EarningsGap DownINVAInnoviva4.2626 of 5 stars$18.54-1.0%$40.33+117.5%-2.4%$1.16B$358.71M-18.36100News CoveragePositive NewsUpcoming EarningsGap UpOPKOPKO Health4.0956 of 5 stars$1.35-1.5%$2.75+103.7%-11.9%$1.07B$689.41M-19.282,997Earnings ReportGap DownGERNGeron3.0375 of 5 stars$1.15-8.7%$4.61+301.0%-74.4%$732.46M$76.99M-5.48229Upcoming Earnings Related Companies and Tools Related Companies Alkermes Alternatives Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives BioCryst Pharmaceuticals Alternatives Celldex Therapeutics Alternatives Dynavax Technologies Alternatives Novavax Alternatives Innoviva Alternatives OPKO Health Alternatives Geron Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNKD) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNKD Stock Alerts